- The company submitted an updated manuscript detailing a new two-step method to remove nearly all non-cancer DNA.
- Early results showed no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort.
- VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method for cancer detection.
Shares of VolitionRx (VNRX) gave up a part of its pre-market gains to trade 30% higher on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said it was successful in isolating more than 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients.
VNRX stock breached its 100-day moving average (100-DMA) for the first time since Oct. 8, 2025.
Source: TradingView
The company submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA. This addresses a key challenge in liquid biopsy, where most circulating DNA typically comes from healthy cells.
“Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA,” said Jake Micallef, Chief Scientific Officer of Volition.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years,” Micallef added.
The early results are encouraging, with no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort, VolitionRx said. The company is now working on further testing in early-stage cancers.
VolitionRx’s Capture-Seq Method for Cancer Detection
VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method and novel biomarkers for cancer detection. The technology enables accurate and potentially low-cost testing across multiple cancers.
It works by enriching ultrashort DNA fragments in blood, achieving a 180-fold increase in detection sensitivity. This approach focuses on DNA within chromosome fragments, unlike traditional methods that analyze extracted DNA.
How Did Stocktwits Users React?
Retail sentiment on Stocktwits completely flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.
Despite shedding gains, retail chatter remained primarily bullish, with one user asking for patience.
Another user said buy the dip.
Year-to-date, the stock has shed around 8%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.